LYSARC — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

6 Recruiting

7 Completed trials

7 Countries active

40 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 2 Phase II/III: 2 Phase II: 4 Phase I/II: 3 Phase IV: 1 Phase I (FiH): 1

Oversight events:

4 urgent safety measures 2 unexpected events across 3 trials

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 1 Peripheral T-cell lymphoma unspecified 1 Marginal zone lymphoma refractory 1 Follicular lymphoma 1

Top IMPs

PREDNISONE 3 RITUXIMAB 3 VINCRISTINE SULFATE 3 DOXORUBICIN HYDROCHLORIDE 2 MOSUNETUZUMAB 2 AZACITIDINE 1 BENDAMUSTINE HYDROCHLORIDE 1 BRENTUXIMAB VEDOTIN 1 CYCLOPHOSPHAMIDE 1 CYCLOPHOSPHAMIDE MONOHYDRATE 1 DEXCHLORPHENIRAMINE MALEATE 1 ETOPOSIDE 1

All trials

13 total

PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 Phase I/II 1 country AZACITIDINE; GOLCADOMIDE; ROGINOLISIB; VENETOCLAX
A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit… Recruiting

2023-505834-84-00 Phase II/III 1 country
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Phase III 6 countries DEXCHLORPHENIRAMINE MALEATE; FLUDEOXYGLUCOSE (18F); MOSUNETUZUMAB; OBINUTUZUMAB;…
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Phase III 5 countries BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; MOSUNET…
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Phase IV 2 countries BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE MONOHYDRATE; DOXORUBICIN HYDROCHLORIDE; ET…
A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 Phase II 2 countries VALEMETOSTAT TOSILATE
OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended

2024-512634-15-00 Phase I/II 2 countries
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended

2023-507286-25-00 Phase II 2 countries LENALIDOMIDE; PREDNISONE; RITUXIMAB; TAFASITAMAB; VINCRISTINE SULFATE
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended

2024-513659-34-00 Phase I/II 1 country
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 Phase II 4 countries LACUTAMAB
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Phase I (FiH) 2 countries
BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells th… Ended

2023-508301-25-00 Phase II 1 country
ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Ther… Ended

2024-519336-16-00 Phase II/III 1 country

Showing 1–13 of 13 trials

← All sponsors A–Z